AERIE PHARMACEUTICALS INC short interest in 2022
In 2022, AERIE PHARMACEUTICALS INC's disclosed short interest ran from 9.64% of shares outstanding on 14 Jan 2022 to 2.84% on 15 Nov 2022, a change of -6.80 percentage points. The year's high was 12.36% on 31 Mar 2022 and its low 2.84% on 15 Nov 2022, averaging 7.87% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.06 days on 29 Apr 2022. Full history: AERIE PHARMACEUTICALS INC.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2022 in figures
- Start of year
- 9.64% (14 Jan 2022)
- End of year
- 2.84% (15 Nov 2022)
- Change
- -6.80 pp
- High
- 12.36% (31 Mar 2022)
- Low
- 2.84% (15 Nov 2022)
- Average
- 7.87%
- Highest days to cover
- 14.06 (29 Apr 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 9.64% | 3.98 | |
| 31 Jan 2022 | 9.87% | 6.12 | |
| 15 Feb 2022 | 11.11% | 7.26 | |
| 28 Feb 2022 | 11.34% | 3.66 | results (8-K), 10-K filed |
| 15 Mar 2022 | 11.98% | 6.13 | |
| 31 Mar 2022 | 12.36% | 8.21 | |
| 14 Apr 2022 | 12.06% | 9.48 | |
| 29 Apr 2022 | 11.57% | 14.06 | |
| 13 May 2022 | 11.04% | 7.67 | results (8-K), 10-Q filed |
| 31 May 2022 | 8.32% | 5.08 | |
| 15 Jun 2022 | 6.74% | 5.92 | |
| 30 Jun 2022 | 7.43% | 4.43 | |
| 15 Jul 2022 | 7.70% | 9.09 | |
| 29 Jul 2022 | 7.00% | 7.54 | |
| 15 Aug 2022 | 7.09% | 4.04 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 4.49% | 1.00 | |
| 15 Sep 2022 | 3.37% | 1.00 | |
| 30 Sep 2022 | 3.25% | 1.81 | |
| 14 Oct 2022 | 2.92% | 1.61 | |
| 31 Oct 2022 | 3.08% | 2.19 | |
| 15 Nov 2022 | 2.84% | 3.39 | results (8-K), 10-Q filed |
See also: AERIE PHARMACEUTICALS INC's full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.